Frankfurt
25.11.25 | 15:29
5,650 Euro
+1,80 % +0,100
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.11. | Fortress Biotech, Inc.: Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights | 475 | GlobeNewswire (Europe) | Total net revenue increased 20.5% to $17.6 million for third quarter of 2025 compared to the third quarter of 2024 Fortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma; Fortress received... ► Artikel lesen | |
| 14.11. | Fortress Biotech, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 14.11. | Fortress Biotech, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 11.11. | Fortress Biotech Q3 Earnings Preview | 5 | Seeking Alpha | ||
| 21.10. | Fortress Biotech: Aktie legt zu - Gichtmittel der Tochtergesellschaft erreicht Phase-3-Studie | 6 | Investing.com Deutsch | ||
| FORTRESS BIOTECH INC PREF Aktie jetzt für 0€ handeln | |||||
| 21.10. | Fortress Biotech stock rises after subsidiary's gout treatment enters Phase 3 trials | 2 | Investing.com | ||
| 21.10. | Fortress Biotech, Inc.: Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics' Global Phase 3 Trials of Dotinurad for the Treatment of Gout | 189 | GlobeNewswire (Europe) | MIAMI, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. ("Urica" or the "Company"), a Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress") subsidiary, today announced that Crystalys Therapeutics... ► Artikel lesen | |
| 02.10. | FDA verweigert Zulassung für Medikament von Fortress Biotech wegen Produktionsmängeln | 18 | Investing.com Deutsch | ||
| 02.10. | Fortress Biotech stock faces setback as FDA issues CRL for CUTX-101 | 3 | Investing.com | ||
| 01.10. | Fortress Biotech stock plummets after FDA rejects Menkes disease drug | 13 | Investing.com | ||
| 01.10. | Fortress Biotech plunges as FDA rejects rare disease drug | 12 | Seeking Alpha | ||
| 01.10. | Fortress Biotech, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 01.10. | Fortress Biotech, Inc.: Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $205 Million Series A Financing | 99 | GlobeNewswire (Europe) | Dotinurad is a next-generation URAT1 inhibitor in two Phase 3 clinical trials with potential for best-in-class safety and efficacy Urica sold dotinurad to Crystalys Therapeutics in 2024 in exchange... ► Artikel lesen | |
| 01.10. | Fortress Biotech, Inc.: Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101 | 138 | GlobeNewswire (Europe) | MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced that the U.S.... ► Artikel lesen | |
| 21.08. | Fortress Biotech stock price target lowered to $17 at H.C. Wainwright | 26 | Investing.com | ||
| 14.08. | Fortress Biotech, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 14.08. | Fortress Biotech, Inc.: Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights | 437 | GlobeNewswire (Europe) | Fortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma; Fortress received ~$28 million at closing and is eligible to receive up to an additional $4.8 million under a contingent value right... ► Artikel lesen | |
| 16.07. | Fortress Biotech, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 23.06. | Fortress Biotech, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.06. | Fortress Biotech, Inc. - 8-K, Current Report | 1 | SEC Filings |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| STRYKER | 325,00 | +1,15 % | P/E Ratio Insights for Stryker | ||
| REGENERON PHARMACEUTICALS | 680,00 | +2,91 % | EU-Zulassung für Dupixent bringt neuen Schwung für Sanofi und Regeneron: Sanofi und Regeneron starten durch, nachdem Dupixent bei Hauterkrankung grünes Licht erhält | Die EU-Kommission hat eine entscheidende Zulassungserweiterung für das Entzündungsmedikament Dupixent erteilt. Sanofi und Regeneron rücken mit dieser Zulassung in den Fokus von Anlegern.Regulatorischer... ► Artikel lesen | |
| VIKING THERAPEUTICS | 30,500 | +1,43 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735 | 78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity
Enrollment Completed Ahead of Schedule and Above Target Size, Indicating Strong Interest in... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 7,314 | +0,99 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy | One-time treatment of nex-z led to consistently rapid, deep and durable reduction in serum TTR through three years of follow-upConsistent trend in disease stability or improvement in multiple measures... ► Artikel lesen | |
| TEMPUS AI | 66,50 | 0,00 % | Tempus AI's Data Business Is Expanding and Adding to Revenues: Here's How | ||
| NUREXONE BIOLOGIC | 0,430 | -4,02 % | Countdown: Höchste Biotech-Auszeichnung für NurExone?! | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 2,229 | +2,93 % | Pacific Biosciences: Mit Long-Read-Sequenzierung zum Angriff auf Illumina | ||
| GINKGO BIOWORKS | 7,550 | +1,34 % | Ginkgo Bioworks Reports Third Quarter 2025 Financial Results | Ginkgo provides an update on its third quarter financial results
BOSTON, Nov. 6, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,365 | +0,46 % | Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence (AI) Stock? | ||
| IOVANCE BIOTHERAPEUTICS | 2,110 | -2,56 % | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | ||
| CYTOMX THERAPEUTICS | 3,602 | +4,41 % | CytomX Therapeutics stock holds Overweight rating at Cantor Fitzgerald | ||
| SANA BIOTECHNOLOGY | 3,490 | -1,55 % | Sana Biotechnology (SANA) Wins Analyst Support With Strategic Focus and Cash Strength | ||
| BIOMEA FUSION | 1,025 | +0,99 % | Biomea Fusion, Inc.: Biomea Fusion Announces Positive 52-Week Results from Phase II COVALENT-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient Populations | Icovamenib showed a sustained treatment benefit at Week 52 (9 months past the end of treatment) in the severe insulin-deficient diabetes patient population taking one or more antihyperglycemic medications... ► Artikel lesen | |
| TERNS PHARMACEUTICALS | 23,800 | -2,46 % | BMO Believes Market Undervalues Terns Pharmaceuticals (TERN) Despite Strong Trial Data | ||
| ARCELLX | 73,02 | -2,59 % | Arcellx: Stifel bekräftigt "Buy"-Rating im Vorfeld der ASH-Konferenz 2025 |
FORTRESS BIOTECH INC PREF gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +1,80 % bei einem Aktienkurs von 5,650 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FORTRESS BIOTECH INC PREF finden Sie auf Wallstreet Online.